EUNETWORKS-FIBER-UK-LTD.
21.9.2022 10:01:49 CEST | Business Wire | Press release
euNetworks Fiber UK Limited (“euNetworks”), a Western European bandwidth infrastructure company, has deployed a new ultra low latency route between Basildon and London in the UK that connects the ICE data centre to Interxion LON1 & 2: A Digital Realty Company, and onwards to Slough. These are critical locations for financial markets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220921005083/en/
Paula Cogan, President euNetworks (Photo: Business Wire)
The new route is over 45km long and includes 14km of ultra low latency CoreSmart® cable. Lumenisity® Limited (“Lumenisity”) supplied the award-winning CoreSmart cable, which is based on NANF® hollowcore technology to enable transmission over long distances and is compatible with regular single mode fibre – both major constraints on other hollowcore fibre architectures. The route is the longest commercial deployment of hollowcore fibre technology to date and its use is exclusive to euNetworks and its customers. It is also the first commercial construction of a long distance hybrid route of hollowcore fibre and regular single mode fibre.
Offering euNetworks’ dedicated network platform euTrade, at bandwidths between 1G and 10G, this hybrid route is 10% faster than an equivalent all single mode fibre cable. It’s the third deployment for euNetworks following successful deliveries of the first hollowcore fibre based commercial route in April 2021 and the second in March earlier this year.
“We have successfully delivered increasingly longer deployments of hollowcore fibre in our network, becoming the first fibre provider in the world to utilise the benefits of this new fibre technology in commercial markets,” said Paula Cogan, President of euNetworks. “From the initial 1km pilot, the teams have gone on to deploy hollowcore cable lengths of 7km and 14km on our network, as well as successfully blending hollowcore fibre with regular single mode fibre on this latest route. We continue to be focused on delivering the best possible bandwidth solutions for our customers and look forward to deploying longer routes with Lumenisity in the coming quarters. Leading the market in fibre-based ultra low latency services throughout Europe remains a key focus for euNetworks.”
“We are pleased to partner with euNetworks again, successfully deploying this new route and achieving this hollowcore cable link length”, said Tony Pearson, VP Sales & Marketing at Lumenisity. “We are excited to reach this milestone with euNetworks, and will continue to deliver a unique cable solution offering longer reach and lower latency for their customers.”
Data travels 50% faster in hollowcore cable, reducing latency by 33%, and providing a round trip saving of 3μs (three microseconds) per kilometre. These latency savings are hugely significant in financial trading applications. They can also be scaled to increase the separation of data centres by 50%, whilst maintaining the latency envelope, more than doubling the area of land in which these data centres can be located.
euNetworks’ euTrade solution is a dedicated network platform supporting the bandwidth needs of the financial services community. The company continues to optimise routes between all the key trading exchanges in Europe, and is supporting major exchange moves this year. This focus ensures delivery of the shortest paths and lowest latencies available in the market.
About euNetworks
euNetworks is a critical bandwidth infrastructure company, owning and operating 17 fibre based metropolitan networks connected with a high capacity intercity backbone covering 53 cities in 17 countries across Europe. The company leads the market in data centre connectivity, directly connecting over 480 today. euNetworks is also a leading cloud connectivity provider and offers a targeted portfolio of metropolitan and long haul services including Dark Fibre, Wavelengths, and Ethernet. Wholesale, finance, content, media, mobile, data centre and enterprise customers benefit from euNetworks’ unique inventory of fibre and duct based assets that are tailored to fulfil their high bandwidth needs. For further information visit eunetworks.com.
About Lumenisity® Limited
Lumenisity is an established independent company originally spun out from the world-renowned Optoelectronics Research Centre (ORC) at the University of Southampton. Formed in 2017 to commercialise breakthroughs in the development of hollowcore optical fibre at the ORC, the company has built a team of industry leaders and experts to realise their goal to be the world’s premier high-performance hollowcore fibre optic cable solutions provider offering their customers reliable, deployable, low latency and high bandwidth connections that unlock new capabilities in communication networks. Lumenisity®, NANF® and Coresmart® are registered trademarks of Lumenisity Limited.
Visit our website at: www.lumenisity.com and visit the team on booth 369 at the ECOC 2022 Exhibition in Basel (19th – 21st September) to find out more about our hollowcore cable solutions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220921005083/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom